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The transmission of sexually transmitted infection (STI) pathogens
from an infected donor to the recipient of a semen donation in assisted
conception may result not only in acute infection but also in long-
term reproductive complications or adverse outcomes of pregnancy,
including infection of the offspring. Screening for bacterial STI
pathogens, Chlamydia trachomatis and Neisseria gonorrhoeae is strongly
recommended because these pathogens can cause serious reproduc-
tive complications in the recipients of semen donations and infection
in their offspring. Screening for these pathogens should be performed
using the most sensitive methods, such as nucleic acid amplified tests.
False-negative results due to inhibitory substances in the semen sam-
ple should be monitored using amplification controls. Where speci-
men transport is not a problem and culture facilities are available,
N gonorrhoeae can also be detected by culture. Laboratories perform-
ing screening should subscribe to proficiency programs and have
strict quality controls. Although Trichomonas vaginalis, group B strep-
tococcus and genital mycoplasmas have been associated with adverse
outcomes of pregnancy, the frequent finding of these organisms in
healthy individuals brings into question the validity of mandatory
inclusion of these organisms in the screening panel. Although viral
STI pathogens and Treponema pallidum – the causative agent of
syphilis – may be detected in semen, their presence may be more sen-
sitively detected through antibody testing of the donor. Screening
donors for HIV, hepatitis B and syphilis by serology is uniformly rec-
ommended in all of the guidelines, but the value of screening either
donors or semen samples for cytomegalovirus, herpes simplex viruses
and human papilloma viruses is less clear.
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Dépistage des MTS dans les échantillons de
sperme
La transmission des MTS (maladies transmissibles sexuellement) entre un
donneur infecté et la receveuse d’un don de sperme lors d’une fécondation
artificielle peut entraîner non seulement une infection aiguë chez la mère
et l’enfant, mais également des problèmes de fertilité à long terme. Le
dépistage des bactéries Chlamydia trachomatis et Neisseria gonorrhoeae, en
cause dans les MTS, est fortement recommandé parce que ces agents
pathogènes peuvent provoquer de graves complications au niveau de
l’appareil reproducteur des receveuses et infecter le bébé. Le dépistage de
ces agents pathogènes doit être effectué à l’aide des méthodes les plus
sensibles, comme les tests d’amplification de l’acide nucléique. Les
résultats faussement négatifs dus à des substances inhibitrices dans
l’échantillon de sperme doivent être vérifiés à l’aide de contrôles
d’amplification. Lorsque le transport des spécimens ne pose pas de
problème et que l’établissement dispose de laboratoires d’hématologie, il
est également possible de déceler la présence de N gonorrhoeae au moyen
d’hémocultures. Le laboratoire responsable du dépistage doit souscrire à
des programmes d’homologation et exercer un strict contrôle de la
qualité. Bien que Trichomonas vaginalis, les streptocoques du groupe B et
les mycoplasmes génitaux aient été associés à des effets négatifs sur la
grossesse, la présence fréquente de ces agents chez des individus en bonne
santé remet en question le bien-fondé de leur dépistage systématique.
Bien que les agents viraux responsables des MTS et Treponema pallidum,
l’agent causal de la syphilis, puissent être décelés dans le sperme, leur
présence peut être détectée avec plus de précision par le dépistage des
anticorps chez le donneur. Le dépistage du VIH, de l’hépatite B et de la
syphilis par analyses sérologiques chez les donneurs est systématiquement
recommandé dans toutes les directives, mais l’utilité du dépistage du
cytomégalovirus, de l’herpès simplex et du papillome humain chez les
donneurs et sur les échantillons de sperme est moins claire.
The present guidelines are intended for laboratoriesinvolved in the testing of semen samples to ensure, within
the limitations of existing laboratory methods, that the
donated semen samples are free from pathogens that can cause
sexually transmitted infections (STIs).
Testing of semen specimens for STI pathogens is not rec-
ommended as a means of diagnosis of clinical syndromes in
donors of assisted conception programs, nor should these spec-
imens be used in tests of cure following treatment. Donors
generally undergo vigorous screening for STIs before they are
accepted into a semen donation program (1-6). Individuals
who have been diagnosed with STIs or who have previously
received STI treatment should not be considered suitable
donors for anonymous assisted conception programs.
However, on occasion, the testing of archived semen samples
may be the only method of determining whether an infectious
agent is present when more appropriate specimens are not
available, or when there is a strong wish to use the sperm from
the donor for attempted conception. Semen samples from a
donor who has not been previously tested for hepatitis viruses B
and C, HIV or human T-lymphotropic virus 1/2 should be 
discarded.
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These guidelines, therefore, do not address issues related to
what testing methods should be used for donor screening,
which pathogens should be included in the donor screening
panel, or the frequency of STI screening for individuals in
semen donation programs. Those issues are addressed by
guidelines for STI screening of donors developed by 
various relevant professional societies and disease control
agencies (1-4).
OBJECTIVES OF SCREENING 
SEMEN SAMPLES FOR STIS
The objective of screening semen samples before they are used
for assisted reproduction procedures is to protect the recipients
of semen donations and their offspring from bacterial and viral
STIs and their sequelae by preventing the transmission of STI
pathogens from the donor to the recipient. The transmission of
STI pathogens to the recipient of a semen donation may result
not only in acute infection, but also in long-term reproductive
complications in the recipient and possible adverse outcomes
of pregnancy, including infection in the offspring (6-8).
RATIONALE FOR INCLUSION OF STI
PATHOGENS IN THE SCREENING PANEL
Ideally, the decision on what should be included in the screen-
ing panel should be evidence-based (Table 1). In reality, little
data exist to support such decisions (2,6,7). Although viral
STI pathogens and Treponema pallidum, the causative agent of
syphilis, may be detected in semen, these infections are more
sensitively detected through antibody testing of the donor.
Screening donors for HIV, hepatitis B and syphilis by serology
is uniformly recommended in all of the guidelines, but the value
of screening either donors or semen samples for
cytomegalovirus, herpes simplex viruses and human papilloma
viruses is less clear (7,9,10).
The bacterial STI pathogens Chlamydia trachomatis
and Neisseria gonorrhoeae can cause serious reproductive 
complications such as pelvic inflammatory disease, ectopic
pregnancy and tubal infertility in the recipient, and oph-
thalmia neonatorum and pneumonia in the neonate.
Therefore, tests for C trachomatis and N gonorrhoeae must be
included in the panel for STI screening of semen samples
(1,7,11). Although Trichomonas vaginalis, Group B streptococcus
and the genital mycoplasmas, including Ureaplasma ure-
alyticum, have been associated with adverse outcomes of preg-
nancy, the frequent finding of these organisms in healthy
individuals brings into question the validity of mandatory
inclusion of these organisms in the screening panel (12-14).
GUIDING PRINCIPLES FOR TESTING
LABORATORIES
To ensure that donated semen samples intended for assisted
conception are free of pathogens that cause bacterial and viral
STIs in the recipient, laboratories must use the most sensitive
and specific laboratory tests available for the detection of each
STI pathogen in the screening panel. Because no laboratory
test is 100% sensitive and specific, false-positive and false-
negative results are inevitable. For semen screening, false-
negative results may lead to more serious consequences.
Therefore, every effort should be made to monitor and mini-
mize false-negative results; in particular, those due to inhibi-
tion of nucleic acid-based amplification tests (NAATs). STI
pathogens generally survive the freezing process; therefore,
the screening of STI pathogens in both fresh and cryopre-
served semen samples is essential.
STI SCREENING OF SEMEN SAMPLES
Recommended laboratory tests to be used for screening
C trachomatis: C trachomatis can be diagnosed in the labora-
tory by culture, antigen detection tests such as enzyme
immunoassays, or nucleic acid-based tests with or without
amplification (see Can J Infect Dis Med Microbiol
2005;16[1]:39-44). Culture was recognized as the reference or
‘gold’ standard test in the detection of C trachomatis until the
advent of NAATs (15-19). Although considered to be 100%
specific, culture is technically demanding, requires a cold
chain to preserve specimen viability in transport, and is not
widely available. The use of antigen detection or nucleic acid
hybridization tests is not recommended due to their low sensi-
tivity, especially in asymptomatic individuals. NAATs have
replaced culture as the reference standard for the laboratory
diagnosis of C trachomatis.
Several NAATs are commercially available in Canada, all
of which are more sensitive than culture or enzyme immunoas-
say. These tests detect and amplify nucleic acid from C tra-
chomatis based on technologies such as polymerase chain
reaction (PCR), ligase chain reaction, strand displacement
amplification and transcription-mediated amplification. These
tests have been approved for urine specimens and urethral and
cervical swabs but not for semen specimens. Laboratories must
therefore validate their test sensitivity using chlamydia-
positive control specimens before proceeding with screening.
N gonorrhoeae: Culture remains the gold standard for the lab-
oratory diagnosis of gonorrhea (19,20) (also see Can J Infect Dis
Med Microbiol 2005;16[1]:15-25). Antigen detection tests for
the detection of N gonorrhoeae are commercially available but
their use is not recommended due to low test sensitivity.
NAATs may offer increased sensitivity compared with culture
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TABLE 1
Screening for sexually transmitted infections in semen
specimens
Recommended 
Pathogen detection in semen Detection method
Bacteria
Chlamydia trachomatis ++ NAAT
Neisseria gonorrhoeae ++ Culture/NAAT
Mycoplasmas + Culture/PCR
Group B streptococcus + Culture
Treponema pallidum – (serology) 
Protozoa
Trichomonas vaginalis + Culture/PCR
Viruses
HIV 1 and 2 – (serology) 
Hepatitis B virus – (test for surface antigen)
Hepatitis C virus – (serology)
Cytomegalovirus + (serology)
Herpes simplex virus – NA
Human papillomavirus – NA
Screening of donors using methods in brackets are recommended. 
+ May be considered, but insufficient data for mandatory recommendation; 
++ Strongly recommended; – Semen testing for these pathogens is not 
recommended. NA Not applicable; NAAT Nucleic acid-based amplification
test; PCR Polymerase chain reaction
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for the detection of N gonorrhoeae in settings where preserving
pathogen viability during specimen transport is a problem.
There have been reports of false-positive NAAT results due to
cross-reaction with other Neisseria species (21,22). A positive
finding by NAAT should therefore be confirmed (see below for
confirmatory testing).
NAATs for N gonorrhoeae have been approved for urine
specimens and urethral and cervical swabs but not for semen
specimens. Laboratories must therefore validate their test sen-
sitivity using positive control specimens before proceeding
with screening.
Multiplex NAAT: At the time of writing, there are at least
two commercial NAAT kits available in Canada for the 
simultaneous detection of C trachomatis and N gonorrhoeae in
the same specimen. The comments for the dedicated tests
apply equally to the multiplex tests.
Volume of specimen for testing
The optimal amount of semen that should be used for such
testing is not known. A survey of the literature showed that
10 µL to 100 µL have been used with PCR testing (16-18).
Some sperm banks use a swab dipped into the semen sample,
but whether this sampling method is adequate to maximize the
sensitivity of NAATs is unclear at this time.
Specimen processing
The viscosity and the abundance of human DNA in a semen
specimen may interfere with the ability of the primers to access
the target DNA in order to initiate the annealing step in the
NAAT amplification cycle. Protease digestion or dilution in a
PCR buffer may overcome this interference without sacrificing
test sensitivity. There is no standardized method for specimen
processing. If a swab is dipped into the semen sample, then the
swab should be processed according to the NAAT kit manu-
facturer’s directions.
Monitoring false-positive and false-negative results
False-positive results: False-positive results may occur because
of contamination during laboratory processing. Contamination
can be addressed by stringent quality control measures in the
laboratory (see articles on C trachomatis [Can J Infect Dis Med
Microbiol 2005;16(1):39-44] and N gonorrhoeae [Can J Infect
Dis Med Microbiol 2005;16(1):15-25]).
False-negative results: False-negative results may occur when
the specimen or reaction mix contains substances that are
inhibitory to the amplification reaction. Semen specimens
have been shown to contain substances inhibitory to NAATs,
but the nature of the inhibition is not known. In addition, the
viscosity of semen specimens and the abundance of DNA in
the samples may also compromise the sensitivity of detection.
To ensure that no STI pathogens are transmitted in the
process of assisted conception through donated semen, the
presence of an internal amplification control to monitor inhi-
bition is an absolute requirement. The PCR and strand dis-
placement tests have amplification controls which will flag
false-negative results if the artificial target provided in the
specimen mix is not amplified. The amplification control is
run simultaneously with the C trachomatis and N gonorrhoeae
assays. For assays that do not have an amplification control, it
is important that known quantities of C trachomatis and/or
N gonorrhoeae or a common human housekeeping gene is
spiked into a duplicate specimen to monitor for false 
negatives.
A variety of methods have been shown to be effective in
the resolution of inhibition in specimens for NAAT testing
(22-24), including:
• heating the NAAT-ready sample at 95°C for 10 min;
• leaving the NAAT-ready sample at 4°C overnight;
• purification of the semen specimen using DNA
purification kits or phenol chloroform extraction;
• heating the semen specimen with Chelex (Bio-Rad
Laboratories, Ontario) at 95°C for 15 min, followed by
centrifugation at 13,000 g for 5 min.
Dilution of the specimen has also been shown to be effec-
tive for resolving inhibition, but it is not recommended for
semen testing because it may compromise the sensitivity of
screening.
A negative NAAT result should only be reported if the
internal control result is positive, indicating that the amplifi-
cation reaction was not inhibited.
Indeterminate results
If a result is considered to be indeterminate – that is, border-
line or in the grey zone between a positive and negative
result – retesting using a fresh aliquot of the specimen is rec-
ommended. If the result is indeterminate again, that sample
should not be used in assisted conception procedures.
Confirmatory testing
Positive results by one NAAT may be confirmed using another
NAAT. Alternatively, the same NAAT targeting another gene
may be used. Cultures for N gonorrhoeae should be confirmed
by the use of tests such as carbohydrate fermentation or fluo-
rescent antibodies.
LABORATORY PROFICIENCY AND 
QUALITY ASSURANCE
All testing laboratories performing semen testing must be
accredited. In addition, testing laboratories should subscribe to
national or international proficiency programs for each screen-
ing method used.
In general, laboratories performing NAATs must also fol-
low stringent guidelines for avoiding contamination, such as
unidirectional workflow, and the use of dedicated pipettes and
other equipment.
Screening STI pathogens in semen samples
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